Mounjaro vs Wegovy: Which is Better for Weight Loss?

The landscape of weight loss treatments has been revolutionised by two groundbreaking medications: Mounjaro (tirzepatide) and Wegovy (semaglutide). Both represent significant advances in obesity medicine, yet they work through different mechanisms and show varying degrees of effectiveness. Understanding the differences between these treatments is crucial for anyone considering pharmaceutical intervention for weight loss.

Understanding the Science Behind Each Treatment

Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the incretin hormone naturally produced in your intestines. This hormone signals satiety to your brain and slows gastric emptying, helping you feel fuller for longer periods.

Mounjaro, on the other hand, contains tirzepatide - a dual-action medication that targets both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. This dual mechanism represents a significant advancement in obesity pharmacotherapy, as tirzepatide addresses multiple pathways involved in appetite regulation and glucose metabolism.

The dual receptor approach of Mounjaro may explain why clinical trials have consistently shown superior weight loss results compared to single-receptor medications like Wegovy.

Clinical Trial Results: The Numbers Don't Lie

SURMOUNT-1 Trial Results (Mounjaro)

The pivotal SURMOUNT-1 trial demonstrated remarkable weight loss outcomes with tirzepatide. Participants receiving the highest dose (15mg) achieved an average weight loss of 22.5% over 72 weeks. Even at the 5mg starting dose, participants lost an average of 16% of their body weight.

The trial included 2,539 adults with obesity or overweight with weight-related complications. The results were groundbreaking:

5mg dose: 16.0% average weight loss
10mg dose: 21.4% average weight loss
15mg dose: 22.5% average weight loss

STEP-1 Trial Results (Wegovy)

The STEP-1 trial, which led to semaglutide's approval for weight management, showed significant but more modest results. Participants receiving Wegovy 2.4mg achieved an average weight loss of 14.9% over 68 weeks.

This 68-week study included 1,961 adults and demonstrated:

Average weight loss of 14.9% with semaglutide 2.4mg
83.5% of participants lost at least 5% of their body weight
66.1% achieved at least 10% weight loss

Head-to-Head Comparison Data

Whilst no direct head-to-head trials have been completed, the SURMOUNT-MMO study provided indirect comparison data suggesting tirzepatide's superiority in weight loss outcomes. Research indicates that the dual mechanism of action in Mounjaro consistently produces greater weight reductions across different patient populations.

Mechanism of Action: Single vs Dual Receptor Targeting

Feature	Mounjaro (Tirzepatide)	Wegovy (Semaglutide)
Mechanism	Dual GIP + GLP-1 receptor agonist	Single GLP-1 receptor agonist
Primary Action	Appetite suppression + improved glucose metabolism	Appetite suppression + delayed gastric emptying
Weight Loss Range	16-22.5% (clinical trials)	12-15% (clinical trials)
Starting Dose	2.5mg weekly	0.25mg weekly
Maximum Dose	15mg weekly	2.4mg weekly
Titration Period	20 weeks to maximum dose	16 weeks to maximum dose

The dual receptor approach of tirzepatide appears to provide enhanced metabolic benefits beyond simple appetite suppression. GIP receptors play crucial roles in insulin secretion and fat metabolism, potentially explaining the superior weight loss outcomes observed in clinical trials.

Side Effects and Tolerability

Both medications share similar side effect profiles, primarily affecting the gastrointestinal system. The most common adverse effects include:

Common Side Effects (Both Medications):

Nausea (most frequent initially)
Diarrhoea
Vomiting
Constipation
Abdominal pain
Decreased appetite

Mounjaro-Specific Considerations: Clinical trials suggest that whilst Mounjaro may cause slightly higher rates of gastrointestinal side effects during initial titration, these generally subside as patients adjust to the medication. The dual receptor mechanism doesn't appear to significantly increase the overall side effect burden.

Wegovy-Specific Considerations: Wegovy's side effects are well-documented through extensive clinical experience. The gradual titration schedule helps minimise initial gastrointestinal symptoms, though some patients may experience persistent nausea.

Both medications require careful peptide storage to maintain their effectiveness and safety profile.

NHS Availability and NICE Guidance

Mounjaro on the NHS

Mounjaro received NICE approval through Technology Appraisal TA1026 for weight management in adults with obesity. The criteria for NHS prescription include:

BMI ≥35 kg/m² with at least one weight-related comorbidity, OR
BMI ≥30 kg/m² with specific high-risk conditions
Evidence of previous unsuccessful weight loss attempts
Commitment to lifestyle modification programmes

Access remains limited through specialist weight management services, with significant regional variation in availability.

Wegovy on the NHS

Wegovy is available through NHS specialist services following NICE approval. The prescription criteria are similar to Mounjaro:

Adults with BMI ≥35 kg/m² plus weight-related complications, OR
BMI ≥30 kg/m² with high cardiovascular risk
Previous unsuccessful weight management attempts
Participation in structured lifestyle programmes

Both medications require ongoing monitoring and regular review to ensure continued effectiveness and safety.

Private Prescription Costs in the UK

Private prescription costs vary significantly across different providers:

Mounjaro Private Costs:

Monthly supply: £150-£200
Annual cost: £1,800-£2,400
Initial consultation: £50-£150

Wegovy Private Costs:

Monthly supply: £130-£180
Annual cost: £1,560-£2,160
Initial consultation: £50-£150

These costs don't include monitoring appointments, blood tests, or additional support services that many providers include in comprehensive weight management programmes.

You can use our cost calculator to estimate your total treatment expenses across different providers.

Dosing Schedules and Administration

Mounjaro Dosing Protocol

Mounjaro follows a structured 20-week titration schedule:

Weeks 1-4: 2.5mg weekly
Weeks 5-8: 5mg weekly
Weeks 9-12: 7.5mg weekly (optional)
Weeks 13-16: 10mg weekly
Weeks 17-20: 12.5mg weekly (optional)
Maintenance: Up to 15mg weekly

Wegovy Dosing Protocol

Wegovy uses a 16-week titration approach:

Weeks 1-4: 0.25mg weekly
Weeks 5-8: 0.5mg weekly
Weeks 9-12: 1mg weekly
Weeks 13-16: 1.7mg weekly
Maintenance: 2.4mg weekly

Both medications are administered via weekly subcutaneous injection using pre-filled pens. Proper reconstitution guide knowledge isn't required as both come ready-to-use.

Who Might Prefer Mounjaro?

Ideal Candidates for Mounjaro:

Individuals seeking maximum weight loss potential
Those with both obesity and type 2 diabetes
Patients who haven't achieved sufficient results with single GLP-1 agonists
People willing to tolerate potentially stronger initial side effects for greater long-term benefits

Consider Mounjaro if:

You have significant weight to lose (BMI >40)
Previous GLP-1 treatments showed limited effectiveness
You have concurrent metabolic syndrome
Cost isn't the primary determining factor

Who Might Prefer Wegovy?

Ideal Candidates for Wegovy:

First-time users of GLP-1 medications
Individuals prioritising established long-term safety data
Those seeking a slightly more affordable option
Patients preferring medications with extensive real-world experience

Consider Wegovy if:

You're new to weight loss medications
You prefer treatments with longer market history
Cost considerations are important
You're particularly sensitive to gastrointestinal side effects

Making the Right Choice

The decision between Mounjaro and Wegovy should involve consultation with qualified healthcare providers who can assess your individual circumstances. Factors to consider include:

Current BMI and weight loss goals
Previous experience with similar medications
Existing health conditions
Cost considerations and insurance coverage
Tolerance for side effects during titration
Long-term commitment to lifestyle changes

You might also want to explore our comparison of Wegovy vs Ozempic to understand the full landscape of semaglutide-based treatments.

The Future of Weight Loss Medications

Both Mounjaro and Wegovy represent significant advances, but the field continues evolving. Retatrutide, a triple-action medication targeting GLP-1, GIP, and glucagon receptors, shows even more promising results in early trials.

As our understanding of incretin biology advances, we can expect more sophisticated treatments that offer enhanced effectiveness with improved tolerability profiles.

Conclusion

Both Mounjaro and Wegovy offer effective solutions for weight management, but they serve slightly different needs. Mounjaro's dual-action mechanism provides superior weight loss outcomes, making it ideal for those seeking maximum effectiveness. Wegovy offers proven results with extensive real-world data, appealing to those preferring established treatments.

The choice ultimately depends on your individual circumstances, health goals, and tolerance for both side effects and costs. Consulting with healthcare providers experienced in obesity medicine ensures you make the most appropriate decision for your weight loss journey.

For those interested in exploring alternative approaches, you might consider researching other peptides like BPC-157 or TB-500 for their potential metabolic benefits, though these aren't specifically approved for weight management.

Frequently Asked Questions

Which is more effective for weight loss, Mounjaro or Wegovy?

Clinical trial data suggests Mounjaro (tirzepatide) is more effective for weight loss. The SURMOUNT-1 trial showed average weight loss of up to 22.5% with Mounjaro, compared to 14.9% with Wegovy in the STEP-1 trial. This superior effectiveness is likely due to Mounjaro's dual mechanism targeting both GLP-1 and GIP receptors.

Are the side effects worse with Mounjaro compared to Wegovy?

Both medications have similar side effect profiles, primarily gastrointestinal symptoms like nausea, diarrhoea, and vomiting. Some clinical data suggests Mounjaro may cause slightly more intense initial side effects, but overall tolerability is comparable between the two medications. Most side effects diminish as your body adjusts to the treatment.

Can I get Mounjaro or Wegovy on the NHS?

Both medications are available on the NHS through specialist weight management services, but access is limited and criteria are strict. You typically need a BMI ≥35 with complications or BMI ≥30 with high cardiovascular risk, plus evidence of unsuccessful previous weight loss attempts. Availability varies significantly by region across the UK.

How much do Mounjaro and Wegovy cost privately in the UK?

Private costs for Mounjaro range from £150-£200 monthly (£1,800-£2,400 annually), whilst Wegovy costs approximately £130-£180 monthly (£1,560-£2,160 annually). These prices don't include consultation fees, monitoring appointments, or blood tests that most providers require.

How long does it take to see results with each medication?

Most people begin experiencing appetite suppression within the first few weeks of starting either medication. Significant weight loss typically becomes apparent after 12-16 weeks of treatment. Maximum weight loss is usually achieved between 52-72 weeks of consistent treatment, according to clinical trial data.

Can I switch from Wegovy to Mounjaro or vice versa?

Switching between these medications is possible under medical supervision. If you're switching from Wegovy to Mounjaro, your doctor will typically start you at a low dose of tirzepatide and gradually titrate upward. The timing and approach depend on your current dose, tolerance, and response to your existing treatment.

Which medication has been available longer?

Wegovy (semaglutide) has been available for weight management longer, receiving approval in 2021. Mounjaro (tirzepatide) was initially approved for diabetes in 2022, with weight management indications following later. Wegovy therefore has more extensive real-world safety and effectiveness data.

Do I need to inject these medications forever to maintain weight loss?

Current evidence suggests that both medications need to be continued long-term to maintain weight loss benefits. Clinical trials show that stopping treatment typically results in gradual weight regain. However, the medications should be combined with sustainable lifestyle changes that can help maintain some benefits even after discontinuation.